Loading...
•
Dec 31, 2021
Phathom Q4 2021 Earnings Report
Phathom Pharmaceuticals reported a net loss for Q4 2021 and highlighted pipeline and business progress.
Key Takeaways
Phathom Pharmaceuticals reported a net loss of $35.8 million for the fourth quarter of 2021, driven by a net loss from operations of $33.0 million. Research and development expenses decreased to $13.5 million, while general and administrative expenses increased to $19.5 million.
Net loss for Q4 2021 was $35.8 million, compared to $53.7 million for Q4 2020.
Net loss from operations for Q4 2021 was $33.0 million, including a $4.3 million non-cash charge related to stock-based compensation.
Research and development expenses decreased to $13.5 million in Q4 2021, compared to $41.6 million in Q4 2020.
General and administrative expenses increased to $19.5 million in Q4 2021, compared to $10.8 million in Q4 2020, due to the buildout of the commercial function.
Phathom
Phathom
Forward Guidance
Phathom anticipates an NDA submission for erosive esophagitis in March 2022, FDA approval of vonoprazan-based regimens for H. pylori treatment by May 3, 2022, a U.S. launch of vonoprazan for H. pylori in the second half of 2022, and enrollment completion of a Phase 3 NERD trial in the second half of 2022.
Positive Outlook
- NDA submission for erosive esophagitis (EE) in March 2022.
- FDA approval of vonoprazan-based regimens for H. pylori infection expected by May 3, 2022.
- U.S. launch of vonoprazan for treatment of H. pylori in second half of 2022.
- Enrollment completion of Phase 3 non-erosive reflux disease (NERD) daily dosing trial in the second half of 2022.